Literature DB >> 10666385

Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.

A K Walch1, H F Zitzelsberger, J Bruch, G Keller, D Angermeier, M M Aubele, J Mueller, H Stein, H Braselmann, J R Siewert, H Höfler, M Werner.   

Abstract

To characterize cytogenetic alterations found in Barrett's adenocarcinoma (BA) and, more importantly, its premalignant stages, we studied chromosomal imbalances in various lesions in the histologically proposed metaplasia-dysplasia-carcinoma sequence using comparative genomic hybridization (CGH). Using 30 esophageal adenocarcinoma resection specimens, we were able to study 30 areas of Barrett's adenocarcinoma and 8 lymph node metastases (LN). In addition, we investigated 25 premalignant lesions adjacent to BA derived from a subset of 14 resection specimens including 11 areas of high grade dysplasia (HGD), 8 areas of low grade dysplasia (LGD), and 6 areas of intestinal metaplasia (IM), which were laser-microdissected and studied with CGH. To validate the CGH findings, fluorescence in situ hybridization analysis on 13 BA with probes specific for HER-2/neu and 20q13.2 were performed. The chromosomal alterations most often identified in BA were: gains on 8q (80%), 20q (60%), 2p, 7p and 10q (47% each), 6p (37%), 15q (33%) and 17q (30%). Losses were observed predominantly on the Y-chromosome (76%), 4q (50%), 5q and 9p (43% each), 18q (40%), 7q (33%) and 14q (30%). High-level amplifications were observed on 8q23-qter, 8p12-pter, 7p11-p14, 7q21-31, 17q11-q23. Recurrent chromosomal changes were also identified in metaplastic (gains on 8q, 6p, 10q, losses on 13q, Y, 9p) and dysplastic epithelium (gains on 8q, 20q, 2p, 10q, 15q, losses on Y, 5q, 9p, 13q, 18q). Novel amplified chromosomal regions on chromosomes 2p and 10q were detected in both Barrett's adenocarcinoma and premalignant lesions. An increase of the average number of detected chromosomal imbalances from IM (7.0 +/- 1.7), to LGD (10.8 +/- 2.2), HGD (13.4 +/- 1.1), BA (13.3 +/- 1.4), and LN (22 +/- 1.2) was seen. Although the detection of common chromosomal alterations in premalignant lesions and adjacent carcinomas suggest a process of clonal expansion, the occurrence of several chromosomal changes in an apparently random order relative to one another is striking evidence that clonal evolution is more complex than would be predicted by linear models. This is probably a reflection of the existence of many divergent neoplastic subpopulations and highlights one of the main problems associated with surveillance of Barrett's patients, namely sampling error.

Entities:  

Mesh:

Year:  2000        PMID: 10666385      PMCID: PMC1850031          DOI: 10.1016/S0002-9440(10)64760-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Epidemiology and molecular biology of Barrett's adenocarcinoma.

Authors:  N K Altorki; S Oliveria; D S Schrump
Journal:  Semin Surg Oncol       Date:  1997 Jul-Aug

2.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Authors:  S L Anzick; J Kononen; R L Walker; D O Azorsa; M M Tanner; X Y Guan; G Sauter; O P Kallioniemi; J M Trent; P S Meltzer
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

3.  Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.

Authors:  D Michael; D G Beer; C W Wilke; D E Miller; T W Glover
Journal:  Oncogene       Date:  1997-10-02       Impact factor: 9.867

4.  Clonal genetic alterations in the lungs of current and former smokers.

Authors:  L Mao; J S Lee; J M Kurie; Y H Fan; S M Lippman; J J Lee; J Y Ro; A Broxson; R Yu; R C Morice; B L Kemp; F R Khuri; G L Walsh; W N Hittelman; W K Hong
Journal:  J Natl Cancer Inst       Date:  1997-06-18       Impact factor: 13.506

5.  FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).

Authors:  T T Zou; J Lei; Y Q Shi; J Yin; S Wang; R F Souza; D Kong; Y Shimada; K N Smolinski; B D Greenwald; J M Abraham; N Harpaz; S J Meltzer
Journal:  Oncogene       Date:  1997-07-03       Impact factor: 9.867

6.  Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas.

Authors:  C A Rumpel; S M Powell; C A Moskaluk
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization.

Authors:  H van Dekken; C J Vissers; H W Tilanus; H J Tanke; C Rosenberg
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

Review 8.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

9.  Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas.

Authors:  W El-Rifai; J C Harper; O W Cummings; E R Hyytinen; H F Frierson; S Knuutila; S M Powell
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

10.  Evolution of neoplastic cell lineages in Barrett oesophagus.

Authors:  M T Barrett; C A Sanchez; L J Prevo; D J Wong; P C Galipeau; T G Paulson; P S Rabinovitch; B J Reid
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

View more
  40 in total

1.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

2.  Persistent p53 mutations in single cells from normal human skin.

Authors:  G Ling; A Persson; B Berne; M Uhlén; J Lundeberg; F Ponten
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

3.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

5.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

6.  Pyloric gland adenoma arising in Barrett's esophagus with mucin immunohistochemical and molecular cytogenetic evaluation.

Authors:  Ryoji Kushima; Michael Vieth; Ken-Ichi Mukaisho; Rie Sakai; Hidetoshi Okabe; Takanori Hattori; Horst Neuhaus; Franz Borchard; Manfred Stolte
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

7.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

8.  Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Kevin C Halling; Navtej S Buttar; Louis-Michel Wongkeesong; Alan R Zinsmeister; Shannon M Brankley; Emily G Barr Fritcher; Wytske M Westra; Kausilia K Krishnadath; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

9.  Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium.

Authors:  Weitian Liu; Hejin Hahn; Robert D Odze; Raj K Goyal
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

Review 10.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.